

TITLE: IN VITRO METHOD FOR DETECTING RENAL DISEASE

FIELD OF INTEREST

Biotechnology (Renal Disease, Biomarkers)

CLINICAL NEED

Chronic kidney disease (CKD) is a type of kidney disease in which there is gradual loss of kidney function over a period of months or years. Diagnosis is generally by blood tests to measure the glomerular filtration rate and urine tests to measure albumin. Initial treatments may include medications to manage blood pressure, sugar levels in blood, and lower cholesterol. Severe disease may require replace therapies such as hemodialysis, peritoneal dialysis, or a kidney transplant.

Nowadays, the definition of reliable biomarkers of renal disease progression and the effective treatment thereof is an unmet clinical need.

DESCRIPTION OF THE INVENTION

Researchers are focused on providing a solution to a clear unmet medical need, which is the finding of reliable biomarkers of renal disease progression and the effective treatment thereof. They solve this problem by using the levels of one member of TNF receptor associated factor protein family, which is determined in peripheral blood mononuclear cells (PBMCs) isolated from blood samples obtained from the patient. Researchers propose the use of the biomarker for detecting renal disease, for predicting the response of patients suffering from renal disease to a treatment with vitamin D analogues or derivatives, or for deciding or recommending whether to treat patients suffering from renal disease with vitamin D analogues or derivatives.

TECHNOLOGY KEYWORDS

CKD, renal disease, TNF receptor, biomarkers, vitamin D, PBMCs.

IPR STATUS

Patent application number: EP19382470.

Applicants: IIS-FJD and UAM.

TYPE AND ROLE OF PARTNER

Looking for commercial partners interested in licensing.

Contact details:

Innovation Unit

e-mail: irene.ruano@fjd.es; laura.felipeo@quironsalud.es